Articles On Rhythm Biosciences (ASX:RHY)

Rhythm Biosciences (RHY) has achieved ISO certification for its colorectal cancer-detecting blood test for the fourth year running The company says the milestone is critically important as part of regulatory approvals for its commercial an...

Key points The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19% The diagnostics company released its latest quarterly results today Its colorectal cancer detection product, ColoSTAT, is set t...

Ouch. The ASX has closed the third trading day of the year with a melt down of 2.74%. The Australian sharemarket has suffered its biggest one-day fall in 16 months, since 4 September 2020. The selling has been widespread with every sector...

Rhythm Biosciences (RHY) gains approval for its blood test ColoSTAT to be marketed and sold in the United Kingdom ColoSTAT is a simple, low-cost blood test for detecting colorectal cancer which removes the unpleasantness often associated w...

The Rhythm Biosciences Ltd (ASX: RHY) share price is surging on Thursday afternoon trade. This comes after the company announced two positive updates regarding its ColoSTAT product and a share placement. At the time of writing, the medical...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the move today. This comes after the company revealed its intentions to expand ColoSTAT into new cancer markets. At the time of writing, the medical device company’s shares are tradin...

Rhythm Biosciences (RHY) identifies five new cancer detection markets to expand its platform technology The new markets for breast, cervical, lung, gastric and pancreatic cancer will be explored as part of a research and development progra...

The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is down by 0.40%. Fertility company Virtus Health (ASX:VRT) is being pursued by a takeover offer from BGH Capital. BGH, wh...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Rhythm Biosciences (RHY) restructures board and management team, effective immediately Current Chair Otto Buttula has transitioned to the Executive Chair role and current CEO Glenn Gilbert has been appointed Managing Director The company s...

Cancer diagnostic technology company Rhythm Biosciences (RHY) achieves CE Mark certification for ColoSTAT This certification indicates Rhythm’s products comply with the EU’s IVD Directives, which are a series of legislative requirement to...

Cancer diagnostics company Rhythm Biosciences Ltd (ASX:RHY) got a regulatory boost this morning, with news that CE Mark approval is now complete for its ColoSTAT blood test platform in the European market. Shares in the ~$350m company conti...

The Rhythm Biosciences Ltd (ASX: RHY) share price is on fire on Tuesday morning. At the time of writing, the cancer diagnostics technology company’s shares are up 15% to $1.90. This means the Rhythm Biosciences share price is now up an imp...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The share market looked set to open little changed following a mixed close on Wall Street as rising interest rates boosted lenders and depressed growth stocks. ASX futures inched up a point or 0.01 per cent as the Dow led for a second ni...

Aussie shares looked set to start the week in retreat following a risk-off session in the US after pandemic restrictions tightened in parts of Europe. US stocks ended mixed on Friday as traders rotated out of cyclical sectors into lockdo...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

It was a mixed bag of results for ASX healthcare shares as we walked through October, as some names came in red hot, whilst others missed the mark completely. After a sharp downturn in late September, where it lost around 7% in just one w...

Shares in medical diagnostics company Rhythm Biosciences Ltd (ASX: RHY) are edging higher in afternoon trade today. At the time of writing, Rhythm Biosciences shares are changing hands at $1.59 apiece, which is an almost 3% gain from yest...

The Rhythm Biosciences Ltd (ASX: RHY) share price is lifting in early trade today as the medical technology company released an investor presentation. At the time of writing, Rhythm Biosciences shares are changing hands at $1.50 each, sig...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the move during late morning trade on Thursday. This comes after the medical device company provided an update in regards to its colorectal cancer test kit product, ColoSTAT. At the...

The ASX 200 health stocks index (XHJ) is falling by 0.55% at the time of writing, compared to the broader ASX 200 index which fell by 0.50%. Fibrotic and inflammatory diseases-focused biotech, Pharmaxis (ASX:PXS), has just announced further...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

Rhythm Biosciences (ASX:RHY) has announced the appointment of a new chair with the resignation of incumbent Shane Tanner.

The Rhythm Biosciences Ltd (ASX: RHY) share price was a very strong performer on Wednesday. The predictive diagnostics company’s shares ended the day 12% higher at $1.32. This means the Rhythm Biosciences share price is now up 550% over th...

Highlights CIMIC Group shares dropped even after one of its companies secured a contract extension. Mineral sands player Heavy Minerals made a weak debut on the ASX today. Hotel Property Investments and Vulcan Energy shares are under...

The Rhythm Biosciences Ltd (ASX: RHY) share price is pushing higher on Tuesday. In afternoon trade, the predictive diagnostics company’s shares are up 8.5% to $1.14. Why is the Rhythm Biosciences share price racing higher? Investors have b...

Highlights The ASX 200 was down 12% by 7,416, paring early losses. Six of the 11 indices were trading in the red, while energy gained the most. Energy companies Beach Energy, Woodside, AGL, Santos and Oil Search topped the gainers’ ch...

Just under two years since Otto Buttula became chairman of Rhythm Biosciences (ASX:RHY), it has gained over 500% since – and the boss of the high flying biotech just chipped more in. Buttula, who in the past has headed financial services fi...

The Rhythm Biosciences Ltd (ASX: RHY) share price is charging higher in afternoon trade, up 7% to $1.21 per share. Below we take a look at what’s driving investor interest in the ASX medical diagnostics technology company. What did Rhythm...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Resources and tech stocks led the ASX back into positive territory Thursday. After a drop yesterday, led by tech, the bourse rebounded with the ASX 200 closing 0.52% higher. Resources led gaining 1.51% and tech gaining 2.6%. The only sector...

The ASX tech sector succumbed to the latest selloff in tech equities globally. dragging the rest of the bourse down with it. The ASX 200 retreated 0.7% to close at 7,379 points while the ASX Emerging Companies Index lost 1.06%, closing at 2...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down 0.25% to 7,334.5 points. Four ASX shares that are not letting that hold them back are list...

The Rhythm Biosciences Ltd (ASX: RHY) share price has been a strong performer on Thursday. In afternoon trade, the early cancer detection-focused predictive diagnostics company’s shares are up 6% to 90 cents. This latest gain means the Rhy...

Wall Street mixed as US Federal Reserve says inflation is transitionary US stock markets finished in mixed territories, as investors digested US Fed chairman Jerome Powell’s testimony before a House panel. The Dow Jones finished 0.13% highe...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

In FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over 390 per cent and made an average gain of 821 per cent. Stockhead has compiled a list (see below) of the 100 best performing ASX stocks base...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

Summary The ASX 200 traded lower by 35.20 points or 0.48% at 7,351, weighed down by sharp selling in materials and energy stocks. The market sentiment was dampened by report that the US Fed may announce sooner-than-expected rise in int...

The ASX climbed briefly past 7,400 points in intra-day trade but ultimately closed just short of the milestone at 7,.368, which was 0.09 per cent higher than yesterday. However, the ASX Emerging Companies Index fell by over 1 per cent for t...

Summary The ASX 200 sets a new record by crossing 7,400 level for the first time. The benchmark trades higher by 23.50 points or 0.32% at 7,403 by afternoon. Nine of the 11 sectors are trading higher, with energy gaining the most, ris...

The Rhythm Biosciences Ltd (ASX: RHY) share price is rising following the company’s latest addition to its ColoSTAT clinical trial. In early morning trade, the medical device company’s shares were up 3.57% to $1.015 before retreating to $1...